Sean A. Mccarthy Sells 14,342 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 14,342 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $19.86, for a total value of $284,832.12. Following the completion of the transaction, the chief executive officer now directly owns 18,587 shares of the company’s stock, valued at $369,137.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
CytomX Therapeutics, Inc. (CTMX) traded up $0.31 during trading hours on Friday, hitting $20.23. The company’s stock had a trading volume of 278,865 shares, compared to its average volume of 311,488.
CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.30). The company had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. analysts forecast that CytomX Therapeutics, Inc. will post -1.46 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of CTMX. Wells Fargo & Company MN raised its position in shares of CytomX Therapeutics by 52.8% in the first quarter. Wells Fargo & Company MN now owns 22,424 shares of the biotechnology company’s stock worth $387,000 after buying an additional 7,747 shares in the last quarter. Swiss National Bank raised its position in shares of CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock worth $463,000 after buying an additional 4,300 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of CytomX Therapeutics by 551.5% in the first quarter. JPMorgan Chase & Co. now owns 185,778 shares of the biotechnology company’s stock worth $3,208,000 after buying an additional 157,261 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of CytomX Therapeutics in the first quarter worth $485,000. Finally, American International Group Inc. raised its position in shares of CytomX Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock worth $217,000 after buying an additional 834 shares in the last quarter. Institutional investors own 60.02% of the company’s stock.
CTMX has been the subject of several recent analyst reports. Bank of America Corporation upped their target price on CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Nomura upped their target price on CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 8th. Finally, Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $31.88.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.